384 related articles for article (PubMed ID: 17369525)
1. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
2. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle.
Kaidanovich-Beilin O; Eldar-Finkelman H
J Pharmacol Exp Ther; 2006 Jan; 316(1):17-24. PubMed ID: 16169938
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.
Liang Y; Osborne MC; Monia BP; Bhanot S; Watts LM; She P; DeCarlo SO; Chen X; Demarest K
Metabolism; 2005 Jul; 54(7):848-55. PubMed ID: 15988691
[TBL] [Abstract][Full Text] [Related]
7. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
9. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
Riedel MJ; Gaddy DF; Asadi A; Robbins PD; Kieffer TJ
Gene Ther; 2010 Feb; 17(2):171-80. PubMed ID: 19865180
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q
Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856
[TBL] [Abstract][Full Text] [Related]
12. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes.
Soltani N; Kumar M; Glinka Y; Prud'homme GJ; Wang Q
Gene Ther; 2007 Jun; 14(12):981-8. PubMed ID: 17410180
[TBL] [Abstract][Full Text] [Related]
13. Prolonged remission of diabetes by regeneration of beta cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1.
Liu MJ; Shin S; Li N; Shigihara T; Lee YS; Yoon JW; Jun HS
Mol Ther; 2007 Jan; 15(1):86-93. PubMed ID: 17164779
[TBL] [Abstract][Full Text] [Related]
14. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
Riedel MJ; Lee CW; Kieffer TJ
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
[TBL] [Abstract][Full Text] [Related]
15. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector.
Choi SH; Lee HC
Gene Ther; 2011 Feb; 18(2):155-63. PubMed ID: 20720576
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation.
Chae HY; Kang JG; Kim CS; Lee SJ; Lee M; Kang D; Jun HS; Ihm SH
Transpl Int; 2012 Feb; 25(2):242-9. PubMed ID: 22171669
[TBL] [Abstract][Full Text] [Related]
17. Acute exercise reduces insulin resistance-induced TRB3 expression and amelioration of the hepatic production of glucose in the liver of diabetic mice.
Lima AF; Ropelle ER; Pauli JR; Cintra DE; Frederico MJ; Pinho RA; Velloso LA; De Souza CT
J Cell Physiol; 2009 Oct; 221(1):92-7. PubMed ID: 19492410
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats.
Park S; Hong SM; Ahn IS
Metabolism; 2010 Jan; 59(1):123-33. PubMed ID: 19766272
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.
Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR
Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098
[TBL] [Abstract][Full Text] [Related]
20. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1.
Yoon JC; Puigserver P; Chen G; Donovan J; Wu Z; Rhee J; Adelmant G; Stafford J; Kahn CR; Granner DK; Newgard CB; Spiegelman BM
Nature; 2001 Sep; 413(6852):131-8. PubMed ID: 11557972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
